Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.

Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR.

Nature. 2000 Jun 22;405(6789):962-6.

PMID:
10879539
2.

In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis.

Upton AM, Cho S, Yang TJ, Kim Y, Wang Y, Lu Y, Wang B, Xu J, Mdluli K, Ma Z, Franzblau SG.

Antimicrob Agents Chemother. 2015 Jan;59(1):136-44. doi: 10.1128/AAC.03823-14. Epub 2014 Oct 20.

3.

Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.

Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, Bishai W, Grosset J.

Antimicrob Agents Chemother. 2005 Jun;49(6):2289-93.

4.

Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.

Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, Rose JD, Reynolds RC, Orme IM.

Antimicrob Agents Chemother. 2005 Jun;49(6):2294-301.

5.

[Recent progress in mycobacteriology].

Okada M, Kobayashi K.

Kekkaku. 2007 Oct;82(10):783-99. Japanese.

PMID:
18018602
6.

New anti-tuberculosis drugs with novel mechanisms of action.

Rivers EC, Mancera RL.

Curr Med Chem. 2008;15(19):1956-67. Review.

PMID:
18691051
7.

OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.

Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M.

PLoS Med. 2006 Nov;3(11):e466.

8.

Delamanid Kills Dormant Mycobacteria In Vitro and in a Guinea Pig Model of Tuberculosis.

Chen X, Hashizume H, Tomishige T, Nakamura I, Matsuba M, Fujiwara M, Kitamoto R, Hanaki E, Ohba Y, Matsumoto M.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02402-16. doi: 10.1128/AAC.02402-16. Print 2017 Jun.

9.

6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases.

Thompson AM, Blaser A, Palmer BD, Anderson RF, Shinde SS, Launay D, Chatelain E, Maes L, Franzblau SG, Wan B, Wang Y, Ma Z, Denny WA.

Bioorg Med Chem Lett. 2017 Jun 1;27(11):2583-2589. doi: 10.1016/j.bmcl.2017.03.069. Epub 2017 Mar 27.

PMID:
28462832
10.

OPC-67683.

[No authors listed]

Tuberculosis (Edinb). 2008 Mar;88(2):132-3. doi: 10.1016/S1472-9792(08)70017-9. Review. No abstract available.

PMID:
18486051
11.

Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.

Sasaki H, Haraguchi Y, Itotani M, Kuroda H, Hashizume H, Tomishige T, Kawasaki M, Matsumoto M, Komatsu M, Tsubouchi H.

J Med Chem. 2006 Dec 28;49(26):7854-60.

PMID:
17181168
12.

In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide.

Villar R, Vicente E, Solano B, PĂ©rez-Silanes S, Aldana I, Maddry JA, Lenaerts AJ, Franzblau SG, Cho SH, Monge A, Goldman RC.

J Antimicrob Chemother. 2008 Sep;62(3):547-54. doi: 10.1093/jac/dkn214. Epub 2008 May 23.

13.

In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis.

Ashtekar DR, Costa-Perira R, Nagrajan K, Vishvanathan N, Bhatt AD, Rittel W.

Antimicrob Agents Chemother. 1993 Feb;37(2):183-6.

14.

Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.

Tasneen R, Williams K, Amoabeng O, Minkowski A, Mdluli KE, Upton AM, Nuermberger EL.

Antimicrob Agents Chemother. 2015 Jan;59(1):129-35. doi: 10.1128/AAC.03822-14. Epub 2014 Oct 20.

15.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
16.

Delamanid: first global approval.

Ryan NJ, Lo JH.

Drugs. 2014 Jun;74(9):1041-5. doi: 10.1007/s40265-014-0241-5. Review.

PMID:
24923253
17.

The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis.

Patterson S, Wyllie S, Stojanovski L, Perry MR, Simeons FR, Norval S, Osuna-Cabello M, De Rycker M, Read KD, Fairlamb AH.

Antimicrob Agents Chemother. 2013 Oct;57(10):4699-706. doi: 10.1128/AAC.00722-13. Epub 2013 Jul 15.

18.

Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).

Palmer BD, Sutherland HS, Blaser A, Kmentova I, Franzblau SG, Wan B, Wang Y, Ma Z, Denny WA, Thompson AM.

J Med Chem. 2015 Apr 9;58(7):3036-59. doi: 10.1021/jm501608q. Epub 2015 Mar 27.

PMID:
25781074
19.
20.

Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).

Cherian J, Choi I, Nayyar A, Manjunatha UH, Mukherjee T, Lee YS, Boshoff HI, Singh R, Ha YH, Goodwin M, Lakshminarayana SB, Niyomrattanakit P, Jiricek J, Ravindran S, Dick T, Keller TH, Dartois V, Barry CE 3rd.

J Med Chem. 2011 Aug 25;54(16):5639-59. doi: 10.1021/jm1010644. Epub 2011 Jul 26.

Supplemental Content

Support Center